Total: $120.8 million

Top 2 drugs
Enbrel (arthritis): $49.5 million; Enbrel (psoriasis): $35.1 million
Prolia: $35.3 million
Watch the Enbrel TV commercial here >>

One might wonder why you would have to advertise the second-best-selling drug in the world. But given that in the first half of 2013 Enbrel made up about 32% of Amgen's ($AMGN) sales, it becomes clear as to why it wants to protect that product. Remember, AbbVie's ($ABBV) Humira, the global leader in sales, is also on this list. Last year, Enbrel brought in $4.2 billion in revenue for Amgen, which sells it in the U.S. and Canada. It brought in another $3.7 billion last year for partner Pfizer ($PFE). For the first half of 2013, the arthritis drug's U.S. sales for Amgen were $2.06 billion. The ads must be paying off because that is up 10% from the year before. Enbrel did have a big target on its back, being aimed at by biosimilar makers who wanted a piece of that very big pie, but Amgen managed to dodge many of those arrows when it nabbed extended patent rights in the U.S. before the drug was to lose protection last year. It said its new patent may protect it for another 17 years in the U.S.


Suggested Articles

The triple combo era in cystic fibrosis is here thanks to Vertex' new OK. Five months ahead of schedule, the FDA green-lighted Trikafta Monday.

On the heels of settling bellwether cases for $45 million, Teva is offering $250 million cash and $23 billion in drugs to end all its opioid lawsuits.

Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.